Symbols / TBIO
TBIO Chart
About
Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. It has license agreement with Regeneron Pharmaceuticals, Inc. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 97.67K |
| Enterprise Value | 42.97M | Income | -47.45M | Sales | 17.03M |
| Book/sh | -15.35 | Cash/sh | 2.54 | Dividend Yield | — |
| Payout | 0.00% | Employees | 39 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | 0.01 | P/B | -0.00 | P/C | — |
| EV/EBITDA | -1.50 | EV/Sales | 2.52 | Quick Ratio | 0.87 |
| Current Ratio | 1.23 | Debt/Eq | 420.52 | LT Debt/Eq | — |
| EPS (ttm) | -30.42 | EPS next Y | -18.89 | EPS Growth | — |
| Revenue Growth | -61.80% | Earnings | 2025-06-11 16:00 | ROA | -30.10% |
| ROE | -178.99% | ROIC | — | Gross Margin | 46.87% |
| Oper. Margin | -3.28% | Profit Margin | -267.41% | Shs Outstand | 1.78M |
| Shs Float | 1.24M | Short Float | 7.31% | Short Ratio | 0.42 |
| Short Interest | — | 52W High | 1.55 | 52W Low | 0.00 |
| Beta | 2.53 | Avg Volume | 530.00 | Volume | 3.00 |
| Target Price | — | Recom | None | Prev Close | $0.06 |
| Price | $0.06 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.06
Latest analyst target
3. DCF / Fair value
$-103.48
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.06
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-08-11 | down | Keybanc | Overweight → Sector Weight | — |
- Gossamer Bio stock tumbles 80% on trial miss - Investing.com Mon, 23 Feb 2026 13
- Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits Mon, 23 Feb 2026 16
- Upstream Bio’s stock drops 47% on verekitug Phase II asthma data - Clinical Trials Arena hu, 12 Feb 2026 08
- Why This Biotech Crashed Almost 50% On Its Asthma Win - Investor's Business Daily Wed, 11 Feb 2026 08
- What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance Fri, 30 Jan 2026 08
- Updated: Upstream Bio's stock slides on Phase 2 severe asthma data - Endpoints News Wed, 11 Feb 2026 11
- Why Belite Bio Stock Soared on Monday - Nasdaq Mon, 01 Dec 2025 08
- Why Nuvation Bio Stock Is Skyrocketing Today - The Motley Fool ue, 30 Sep 2025 07
- Q32 Bio Stock (QTTB) Opinions on ADX-097 Asset Sale | QTTB Stock News - Quiver Quantitative Mon, 01 Dec 2025 08
- ‘Zombie’ biotech buyer Xoma to acquire Generation Bio - BioPharma Dive ue, 16 Dec 2025 08
- Zura Bio Stock Pre-Market (-3.6%): Phase 2 Trial Data Delayed to Q4 2026 - Trefis Sat, 24 Jan 2026 08
- Upstream Bio stock tumbles after mixed Phase 2 asthma trial results - Investing.com Wed, 11 Feb 2026 08
- KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - Yahoo Finance hu, 04 Dec 2025 08
- Cabaletta Bio Stock (CABA) Opinions on Insider Buying and Clinical Updates - Quiver Quantitative Fri, 23 Jan 2026 08
- Raymond James reiterates Market Perform rating on Korro Bio stock - Investing.com Wed, 28 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 8390 | — | — | Stock Award(Grant) at price 0.00 per share. | GOLUB STEVEN J | Director | — | 2024-07-24 00:00:00 | D |
| 1 | 8390 | — | — | Stock Award(Grant) at price 0.00 per share. | HLAVINKA SARAH E | Director | — | 2024-07-24 00:00:00 | D |
| 2 | 8390 | — | — | Stock Award(Grant) at price 0.00 per share. | WEISSMAN JAMES B. | Director | — | 2024-07-24 00:00:00 | D |
| 3 | 8390 | — | — | Stock Award(Grant) at price 0.00 per share. | KRUEGER TODD | Director | — | 2024-07-24 00:00:00 | D |
| 4 | 8390 | — | — | Stock Award(Grant) at price 0.00 per share. | HODGES MICHAEL R. | Director | — | 2024-07-24 00:00:00 | D |
| 5 | 95106 | nan | — | — | WITNEY FRANKLIN R. PH.D. | Director | — | 2024-05-01 00:00:00 | D |
| 6 | 83861 | nan | — | — | TSINGOS CHRISTINE A | Director | — | 2024-05-01 00:00:00 | D |
| 7 | 81049 | nan | — | — | NACHTSHEIM JAMI DOVER K | Director | — | 2024-05-01 00:00:00 | D |
| 8 | 31486 | nan | — | — | HERREMA GREGORY J | Director | — | 2024-05-01 00:00:00 | D |
| 9 | 83158 | nan | — | — | TUMOLO ANNETTE | Director | — | 2024-05-01 00:00:00 | D |
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | -2.32M | -150.99K | -577.53K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -29.43M | -42.90M | -33.86M |
| TotalUnusualItems | -11.06M | -719.00K | -2.14M |
| TotalUnusualItemsExcludingGoodwill | -11.06M | -719.00K | -2.14M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -47.72M | -48.47M | -38.96M |
| ReconciledDepreciation | 4.10M | 2.88M | 1.57M |
| ReconciledCostOfRevenue | 10.56M | 11.84M | 6.74M |
| EBITDA | -40.49M | -43.62M | -36.00M |
| EBIT | -44.59M | -46.49M | -37.58M |
| NetInterestIncome | -1.36M | -1.22M | -1.37M |
| InterestExpense | 3.10M | 1.96M | 1.37M |
| InterestIncome | 1.74M | 738.00K | |
| NormalizedIncome | -38.99M | -47.90M | -37.40M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -47.72M | -48.47M | -38.96M |
| TotalExpenses | 62.66M | 73.92M | 46.42M |
| TotalOperatingIncomeAsReported | -46.54M | -46.48M | -35.37M |
| DilutedAverageShares | 1.66M | 1.64M | 1.01M |
| BasicAverageShares | 1.66M | 1.64M | 1.01M |
| DilutedEPS | -29.52 | -29.70 | -38.52 |
| BasicEPS | -29.52 | -29.70 | -38.52 |
| DilutedNIAvailtoComStockholders | -49.02M | -48.47M | -38.96M |
| NetIncomeCommonStockholders | -49.02M | -48.47M | -38.96M |
| PreferredStockDividends | 1.30M | ||
| NetIncome | -47.72M | -48.47M | -38.96M |
| NetIncomeIncludingNoncontrollingInterests | -47.72M | -48.47M | -38.96M |
| NetIncomeContinuousOperations | -47.72M | -48.47M | -38.96M |
| TaxProvision | 24.00K | 24.00K | 14.00K |
| PretaxIncome | -47.70M | -48.45M | -38.94M |
| OtherIncomeExpense | -11.19M | -745.00K | -2.20M |
| OtherNonOperatingIncomeExpenses | -130.00K | -26.00K | -62.00K |
| SpecialIncomeCharges | -11.39M | -727.00K | -618.00K |
| OtherSpecialCharges | 727.00K | 618.00K | |
| ImpairmentOfCapitalAssets | 11.39M | 0.00 | |
| GainOnSaleOfSecurity | 331.00K | 8.00K | -1.52M |
| NetNonOperatingInterestIncomeExpense | -1.36M | -1.22M | -1.37M |
| InterestExpenseNonOperating | 3.10M | 1.96M | 1.37M |
| InterestIncomeNonOperating | 1.74M | 738.00K | |
| OperatingIncome | -35.15M | -46.48M | -35.37M |
| OperatingExpense | 52.10M | 62.08M | 39.67M |
| ResearchAndDevelopment | 17.50M | 23.46M | 14.47M |
| SellingGeneralAndAdministration | 34.60M | 38.62M | 25.21M |
| SellingAndMarketingExpense | 13.51M | 16.49M | 10.96M |
| GeneralAndAdministrativeExpense | 21.09M | 22.13M | 14.25M |
| OtherGandA | 21.09M | 22.13M | 14.25M |
| GrossProfit | 16.95M | 15.60M | 4.30M |
| CostOfRevenue | 10.56M | 11.84M | 6.74M |
| TotalRevenue | 27.51M | 27.43M | 11.04M |
| OperatingRevenue | 27.51M | 27.43M | 11.04M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 1.67M | 1.65M | 1.63M |
| ShareIssued | 1.67M | 1.65M | 1.63M |
| NetDebt | 3.70M | ||
| TotalDebt | 34.38M | 21.43M | 17.32M |
| TangibleBookValue | -4.63M | 29.80M | 74.06M |
| InvestedCapital | 5.51M | 66.21M | 105.47M |
| WorkingCapital | 22.17M | 41.59M | 83.45M |
| NetTangibleAssets | 24.67M | 29.80M | 74.06M |
| CapitalLeaseObligations | 29.11M | 1.78M | 2.63M |
| CommonStockEquity | 238.00K | 46.56M | 90.78M |
| PreferredStockEquity | 29.30M | ||
| TotalCapitalization | 34.81M | 66.21M | 104.87M |
| TotalEquityGrossMinorityInterest | 29.54M | 46.56M | 90.78M |
| StockholdersEquity | 29.54M | 46.56M | 90.78M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -3.00K | 0.00 |
| OtherEquityAdjustments | -3.00K | ||
| RetainedEarnings | -161.47M | -113.74M | -65.27M |
| AdditionalPaidInCapital | 161.70M | 160.30M | 156.05M |
| CapitalStock | 29.30M | 5.00K | 5.00K |
| CommonStock | 5.00K | 5.00K | 5.00K |
| PreferredStock | 29.30M | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 40.87M | 34.80M | 25.47M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 32.69M | 21.30M | 15.74M |
| DerivativeProductLiabilities | 36.00K | 367.00K | 108.00K |
| NonCurrentDeferredLiabilities | 95.00K | 142.00K | 150.00K |
| NonCurrentDeferredRevenue | 95.00K | 142.00K | 150.00K |
| LongTermDebtAndCapitalLeaseObligation | 32.56M | 20.79M | 15.48M |
| LongTermCapitalLeaseObligation | 27.29M | 1.14M | 1.39M |
| LongTermDebt | 5.27M | 19.65M | 14.09M |
| CurrentLiabilities | 8.18M | 13.50M | 9.73M |
| OtherCurrentLiabilities | 92.00K | 373.00K | 335.00K |
| CurrentDeferredLiabilities | 338.00K | 3.96M | 205.00K |
| CurrentDeferredRevenue | 338.00K | 3.96M | 205.00K |
| CurrentDebtAndCapitalLeaseObligation | 1.82M | 637.00K | 1.84M |
| CurrentCapitalLeaseObligation | 1.82M | 637.00K | 1.24M |
| CurrentDebt | 603.00K | ||
| OtherCurrentBorrowings | 603.00K | ||
| PayablesAndAccruedExpenses | 5.93M | 8.53M | 7.35M |
| CurrentAccruedExpenses | 2.65M | 7.24M | 4.85M |
| Payables | 3.28M | 1.29M | 2.50M |
| AccountsPayable | 3.28M | 1.29M | 2.50M |
| TotalAssets | 70.41M | 81.36M | 116.26M |
| TotalNonCurrentAssets | 40.06M | 26.27M | 23.07M |
| OtherNonCurrentAssets | 676.00K | 981.00K | 609.00K |
| GoodwillAndOtherIntangibleAssets | 4.86M | 16.77M | 16.73M |
| OtherIntangibleAssets | 1.37M | 1.88M | 2.40M |
| Goodwill | 3.50M | 14.89M | 14.33M |
| NetPPE | 34.52M | 8.52M | 5.74M |
| AccumulatedDepreciation | -3.47M | -1.94M | -793.00K |
| GrossPPE | 37.99M | 10.46M | 6.53M |
| Leases | 332.00K | 58.00K | 95.00K |
| ConstructionInProgress | 586.00K | 1.50M | 1.54M |
| OtherProperties | 27.22M | 1.66M | 2.28M |
| MachineryFurnitureEquipment | 9.86M | 7.24M | 2.62M |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 30.35M | 55.09M | 93.18M |
| OtherCurrentAssets | 1.01M | 3.29M | 4.34M |
| RestrictedCash | 175.00K | 175.00K | 0.00 |
| PrepaidAssets | 4.34M | ||
| Inventory | 4.03M | 2.20M | 2.37M |
| FinishedGoods | 968.00K | 509.00K | 510.00K |
| WorkInProcess | 1.03M | 647.00K | 896.00K |
| RawMaterials | 2.03M | 1.04M | 962.00K |
| Receivables | 5.99M | 5.85M | 3.67M |
| AccountsReceivable | 5.99M | 5.85M | 3.67M |
| AllowanceForDoubtfulAccountsReceivable | -1.29M | -343.00K | 0.00 |
| GrossAccountsReceivable | 7.27M | 6.19M | 3.67M |
| CashCashEquivalentsAndShortTermInvestments | 19.16M | 43.58M | 82.81M |
| OtherShortTermInvestments | 17.59M | 13.16M | 0.00 |
| CashAndCashEquivalents | 1.57M | 30.42M | 82.81M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -36.65M | -43.18M | -38.55M |
| RepaymentOfDebt | -15.09M | -15.08M | -5.08M |
| IssuanceOfDebt | 0.00 | 19.76M | 14.87M |
| IssuanceOfCapitalStock | 18.41M | 0.00 | 112.48M |
| CapitalExpenditure | -1.98M | -4.47M | -1.85M |
| InterestPaidSupplementalData | 2.23M | 1.38M | 825.00K |
| IncomeTaxPaidSupplementalData | 24.00K | 0.00 | |
| EndCashPosition | 1.75M | 30.59M | 82.81M |
| BeginningCashPosition | 30.59M | 82.81M | 13.46M |
| ChangesInCash | -28.85M | -52.21M | 69.34M |
| OtherCashAdjustmentInsideChangeinCash | -3.00K | 0.00 | |
| FinancingCashFlow | 11.56M | 4.51M | 121.08M |
| CashFlowFromContinuingFinancingActivities | 11.56M | 4.51M | 121.08M |
| NetOtherFinancingCharges | -752.00K | -1.37M | |
| ProceedsFromStockOptionExercised | 8.25M | 580.00K | 173.00K |
| NetPreferredStockIssuance | 18.41M | 0.00 | |
| PreferredStockIssuance | 18.41M | 0.00 | |
| NetCommonStockIssuance | 0.00 | 112.48M | |
| CommonStockIssuance | 0.00 | 112.48M | |
| NetIssuancePaymentsOfDebt | -15.09M | 4.68M | 9.79M |
| NetLongTermDebtIssuance | -15.09M | 4.68M | 9.79M |
| LongTermDebtPayments | -15.09M | -15.08M | -5.08M |
| LongTermDebtIssuance | 0.00 | 19.76M | 14.87M |
| InvestingCashFlow | -5.74M | -18.01M | -15.04M |
| CashFlowFromContinuingInvestingActivities | -5.74M | -18.01M | -15.04M |
| NetInvestmentPurchaseAndSale | -3.78M | -12.98M | 0.00 |
| SaleOfInvestment | 30.00M | 64.44M | 0.00 |
| PurchaseOfInvestment | -33.77M | -77.43M | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | -556.00K | -13.19M |
| PurchaseOfBusiness | 0.00 | -556.00K | -13.19M |
| NetPPEPurchaseAndSale | -1.96M | -4.47M | -1.85M |
| SaleOfPPE | 16.00K | 0.00 | |
| PurchaseOfPPE | -1.98M | -4.47M | -1.85M |
| OperatingCashFlow | -34.67M | -38.72M | -36.70M |
| CashFlowFromContinuingOperatingActivities | -34.67M | -38.72M | -36.70M |
| ChangeInWorkingCapital | -7.77M | 1.79M | -3.04M |
| ChangeInOtherWorkingCapital | -3.67M | 3.74M | -542.00K |
| ChangeInOtherCurrentLiabilities | -179.00K | -1.44M | -776.00K |
| ChangeInPayablesAndAccruedExpense | -3.29M | 1.16M | 4.39M |
| ChangeInPrepaidAssets | 2.52M | 685.00K | -3.92M |
| ChangeInInventory | -1.82M | 168.00K | -1.46M |
| ChangeInReceivables | -1.33M | -2.53M | -735.00K |
| ChangesInAccountReceivables | -1.33M | -2.53M | -735.00K |
| OtherNonCashItems | 765.00K | 482.00K | 333.00K |
| StockBasedCompensation | 3.96M | 3.73M | 1.09M |
| ProvisionandWriteOffofAssets | 1.20M | 343.00K | |
| AssetImpairmentCharge | 11.63M | 0.00 | 0.00 |
| AmortizationOfSecurities | -643.00K | -179.00K | 0.00 |
| DepreciationAmortizationDepletion | 4.10M | 2.88M | 1.57M |
| DepreciationAndAmortization | 4.10M | 2.88M | 1.57M |
| AmortizationCashFlow | 515.00K | 515.00K | 458.00K |
| AmortizationOfIntangibles | 515.00K | 515.00K | 458.00K |
| Depreciation | 3.59M | 2.36M | 1.12M |
| OperatingGainsLosses | -195.00K | 721.00K | 2.30M |
| GainLossOnInvestmentSecurities | -331.00K | -8.00K | 1.66M |
| GainLossOnSaleOfPPE | 136.00K | 2.00K | |
| NetIncomeFromContinuingOperations | -47.72M | -48.47M | -38.96M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for TBIO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|